Ascentage Pharma Group International (NASDAQ:AAPG) Sees Strong Trading Volume – Time to Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares saw an uptick in trading volume on Thursday . 5,773 shares traded hands during mid-day trading, a decline of 15% from the previous session’s volume of 6,823 shares.The stock last traded at $17.45 and had previously closed at $16.81.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. BTIG Research reaffirmed a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. Finally, B. Riley Financial started coverage on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. They set a “buy” rating and a $45.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company’s stock. According to MarketBeat, Ascentage Pharma Group International presently has a consensus rating of “Buy” and an average price target of $46.43.

Ascentage Pharma Group International Trading Up 1.4%

The business has a 50-day simple moving average of $18.24 and a 200-day simple moving average of $20.74. The company has a current ratio of 1.22, a quick ratio of 1.18 and a debt-to-equity ratio of 1.09.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share for the quarter. The business had revenue of $22.24 million for the quarter. On average, research analysts predict that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 EPS for the current year.

Institutional Investors Weigh In On Ascentage Pharma Group International

Institutional investors have recently bought and sold shares of the company. Citadel Advisors LLC purchased a new stake in Ascentage Pharma Group International during the 3rd quarter worth approximately $383,000. UBS Group AG lifted its position in shares of Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares in the last quarter. Finally, Hsbc Holdings PLC acquired a new stake in shares of Ascentage Pharma Group International in the second quarter worth approximately $391,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.